EBASTEL

This brand name is authorized in Brazil, Cyprus, Germany, Japan, Spain.

Active ingredients

The drug EBASTEL contains one active pharmaceutical ingredient (API):

1	Ebastine UNII TQD7Q784P1 - EBASTINE
	Ebastine has been shown to produce a rapid and long-lasting inhibition of histamine-induced effect and to have a strong affinity towards H1-receptors.
	Read more about Ebastine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
EBASTEL Film-coated tablet	MPI, EU: SmPC	Υπουργείο Υγείας (CY)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R06AX22	Ebastine	R Respiratory system → R06 Antihistamines for systemic use → R06A Antihistamines for systemic use → R06AX Other antihistamines for systemic use
Discover more medicines within R06AX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	508006602115311, 508006701131315, 508021070141007
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00027140, 00027157, 02249620, 02249637, 02249643, 02748955, 02748961, 02950869, 04260270, 04260287, 04260293, 04445940, 07117248, 07275705, 07275711, 07275728, 09284186, 09284200, 09284217, 09477057, 09477063, 10944564, 10944570, 15255645, 15255651, 15255668
ES	Centro de información online de medicamentos de la AEMPS	58357, 58358, 63366, 66281, 66282
JP	医薬品医療機器総合機構	4490019F1028, 4490019F2024, 4490019F3020, 4490019F4027